Abstract
Renal cancer accounts for 2 to 3% of all malignant tumors. An estimated 39,000 new cases and 13,000 deaths were predicted for 2006.1 Renal cancer is diagnosed in patients ranging from 40 to 70 years of age, with a male predominance of 1.6 to 1.0.1 A comparison of 43,685 cases of renal cancer diagnosed in the period 1973 to 1985 with those diagnosed from 1986 to 1998 (Surveillance, Epidemiology, and End Results [SEER] database) demonstrated a marginal increase in the proportion of localized cancers and a decrease in advanced cases in the latter group. The differences were not significant, and importantly, overall survival was not improved.2 While increased imaging and laboratory testing may generally explain the increased incidence, other factors may play a role.2
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
American Cancer Society. Cancer Facts and Figures 2006. Atlanta, GA: American Cancer Society, 2006.
Hock LM, Lynch J, Balaji KC. Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: of Surveillance, Epidemiology and End Results program data. J Urol 2002;167:57–60.
Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005;353:2477–2490.
Russo P. Renal cell carcinoma: presentation, staging, and surgical treatment. Semin Oncol 2000;27:160–176.
Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumours. J Pathol 1997;183:131–133.
Kim WY, Kaelin WG. The Role of VHL gene mutation in Human Cancer. J Clin Oncol 2004;22:4991–5004.
Novick AC. Nephron-sparing surgery for renal cell carcinoma. Annu Rev Med 2002;53:393–407.
Linehan WM, Vasselli J, Srinivasan R, et al. Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Can Res 2004;10:6282s–6289s.
Gill IS. Minimally invasive nephron-sparing surgery. Urol Clin North Am 2003;30:551–579.
Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004;171:1071–1076.
Permpongkosol S, Chan DY, Link RE, Sroka M, Allaf M, Varkarakis I, Lima G, Jarrett TW, Kavoussi LR. Long-term survival analysis after laparoscopic radical nephrectomy. J Urol 2005;174:1222–1225.
Hollenbeck BK, Taub DA, Miller DC, Dunn RL, Wei JT. National utilization trends of partial nephrectomy for renal cell carcinoma: a case of underutilization. Urology 2006;67:254–259.
Leibovich BC, Blute ML, Cheville, Lohse CM, Weaver AL, Zincke H. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol 2004;171:1066–1070.
Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21:3127–3132.
McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23:133–141.
Medical Research Council and Collaborators. Interferon alfa and survival in metastatic renal carcinoma: early results of a randomized controlled trial. Lancet 1999;353:14–17.
Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289–296.
Mekhail TM, Abou-Jawde RM, BouMerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005;23:832–841.
Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9(6):669–676.
Motzer RJ, Hutson TE, Tomczak P, et al. Phase III randomized trial of sunitinib malate (SU 11248) versus interferon-alfa (IFN-a) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2006;24(18S, pt II):930s.
Escudier B, Szczylik C, Demkow T, et al. Randomized phase II trial of the multi-kinase inhibitor sorafenib versus interferon (IFN) in treatment-naïve patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2006;24 (18S pt I):217s.
Hudes GR, Carducci M, Tomczak P, et al. A phase III, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). J Clin Oncol 2006;24(18S pt II):930s.
Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349(5):427–434.
Bukowski R, Kabbinavar F, Figlin RA, et al. Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC). J Clin Oncol 2006;24(18S pt I):222s.
Genentech Press Release. www.gene.com.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Bukowski, R.M., Novick, A.C. (2008). Renal Cell Carcinoma: Background . In: Bukowski, R.M., Novick, A.C. (eds) Clinical Management of Renal Tumors. Humana Press. https://doi.org/10.1007/978-1-60327-149-3_1
Download citation
DOI: https://doi.org/10.1007/978-1-60327-149-3_1
Publisher Name: Humana Press
Print ISBN: 978-1-58829-251-3
Online ISBN: 978-1-60327-149-3
eBook Packages: MedicineMedicine (R0)